GLB1 and amyloidosis: By delivering anti-amyloid antibodies in the brains of AD mice through K16ApoE, and observing that the delivered antibodies label the amyloid plaques in a manner almost indistinguishable to identifying the plaques through standard immunohistochemistry coupled with the demonstration that the delivered molecules retains biological activity (results of the beta-galactosidase based experiments) raises the possibility that K16ApoE has potential for clinical applications.